Success stories

WE ATTEND CONGRESSES ON YOUR BEHALF

In the current context, it is up to us to adapt to the new changes and move forward. It is up to us, you, healthcare professionals, everybody. It is time to rethink our ways of interacting, reaching people, sharing experiences, ensuring that research and clinical developments move forward and patients have the best means at their fingertips to overcome their diseases.

To this end, medical updates and scientific developments, which are regularly presented at congresses, play a vital role. These congresses have also undergone a major transformation as a result of the changes experienced throughout this year, for the most part by converting to a virtual format. We’ve traded coffee talks for avatar walks, but congresses still bring much-needed scientific and medical news.

SEPAR produces a consensus document on severe asthma

On 1 and 2 June 2017, as part of the SEPAR congress, the first working session of the Asthma Regional Forum took place. During the session, 40 prominent pulmonologists from all of Spain’s autonomous communities ratified a set of recommendations on severe asthma contained in a consensus document that is in the final drafting phase.

In order to achieve the objectives set out at the ratification meeting for the recommendations, the project coordinating group, together with the project’s scientific committee, developed these materials. This document covers key aspects of pathology such as its definition, diagnosis, treatment, adherence to it and preventive measures.

RESCAL, a pioneering tool developed by the SEAIC to strengthen quality and safety in patient care

The Spanish Society of Allergology and Clinical Immunology (SEAIC) has created the RESCAL document (Safety and Quality Recommendations in Allergology), with the aim of providing a series of recommendations on the materials, structures, physical spaces and human resources required to ensure quality and safety in patient care, as well as the recommended timescales for carrying out each activity.

According to Dr Mar Reaño, co-author of the handbook and chair of the SEAIC Committee on Quality and Safety Of Care: “The human resources, time, and technicians required for the performance of allergological practice under adequate conditions of safety and quality vary from one procedure to another, hence this new document to cover a logistical gap in the allergological field and, in parallel, it aims to respond to the soaring increase in allergic people being recorded in Spain.”

Our contribution to the fight against cancer

Since 1998 and with only one year’s break, GOC has been responsible for managing and ensuring the achievement of the objectives of the early breast cancer screening programme at the Hospital de la Vall d’Hebron, operating as a technical office for Barcelona’s districts of Horta-Guinardó and Nou Barris. Over the course of these 20 years, more than 220,000 women have participated in the programme, allowing nearly 1,000 hidden neoplasms to be detected and treated early.

In addition, our health contact centre has been providing this same service since 2001 to the entire female population between the ages of 50 and 64 of the province of Girona, working with the preventive medicine service at the Hospital de Salt and the screening units at the Fundació Salut Empordà-Hospital de Figueres, Hospital de Olot, Hospital Comarcal de la Garrotxa, Hospital Comarcal de Blanes, Hospital de Sant Jaume de Calella and Hospital Comarcal de Campdevànol.

Consensus paper on the treatment of patients with NSCLC, with EGFR mutation and synchronous involvement of the central nervous system

Lung cancer currently accounts for 14% of all cancer diagnoses and is the leading cause of cancer deaths in men and women (1, 2). 85-90% of lung cancers are non-microcytic (NSCLC) or non-small cells, which can occur with brain metastases with an incidence of between 20 and 40% (3). From a molecular point of view, 15% of the causes of NSCLCs lie in a mutation in the epidermal growth factor receptor (EGFR) gene (4).

Despite their high prevalence, patients of these characteristics, i.e. those with NSCLC with EGFR mutation and brain metastases, have generally been excluded from clinical trials, so there is a lack of evidence regarding suitability in terms of their management and the treatment that they should follow.

Grunenthal Pharma is committed to improving the pharmaceutical distribution model nationwide

With the participation of 17 representatives from the main national distributors in the pharmaceutical sector and 2 professionals from Grunenthal Pharma, the second edition of the national meeting of the Wholesale Channel and the laboratory driving the initiative was held in Madrid last September.

The objective of the meeting was to analyse the sector’s current situation and identify the aspirational short and long-term improvements. Through GOC methodological support the meeting was streamlined using a structured brainstorming technique (Metaplan®) and conducted through an appreciative research model focused on identifying strengths, opportunities, aspirations and outcomes. At the 31st Edition of the European Pharmacy Office Congress in 2019, a poster was presented in infographic format showing the results obtained.